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Neural stem cells (NSCs) offer a unique and powerful tool for basic research and regenerative medicine. However,
the challenges that scientists face in the comprehension of the biology and physiological function of these cells are
still many. Deciphering NSCs fundamental biological aspects represents indeed a crucial step to control NSCs fate
and functional integration following transplantation, and is essential for a safe and appropriate use of NSCs in
injury/disease conditions. In this review, we focus on the biological properties of NSCs and discuss how these cells
may be exploited to provide effective therapies for neurological disorders. We also review and discuss ongoing
NSC-based clinical trials for these diseases.
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Introduction
Conventional pharmacological treatments for most neuro-
degenerative conditions relieve some symptoms but rarely
vary the course of the disease or halt its progression. Graft-
ing of human fetal tissue has provided a proof of concept
for cell therapy approaches to neurodegenerative diseases
in a number of clinical studies, including treatment of
Parkinson’s and Huntington’s disease patients [1]. Nonethe-
less, this does not represent a practical route for large-scale
therapeutic applications due to limited availability and
quality of human fetal tissue, as well as for ethical
considerations.
To this regard, in the last years, great media consider-
ation has brought neural stem cell (NSC) research into the
spotlight. Most of this attention has been raised by the
stimulating prospects of NSCs application for cell replace-
ment therapies for neurological disorders, engendering
hopes and expectations in the public and, particularly, in
patients. Despite the evident benefits pledged by the NSC
field and some encouraging preliminary studies in animal
models, there still remains a gap between theory and
practice. Indeed, while stem cell-based therapies are the
current standard of care for blood tumors and are gaining* Correspondence: luciano.conti@unitn.it
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disorders, applications for diseases affecting the nervous
system yet represent a pioneering field, being in the early
phases of clinical scrutiny. What is still missing to effect-
ively translate NSC research into clinical applications? Al-
though important scientific progresses in the field have
been achieved, we still lack a profound understanding of
the basic biology of NSCs and how to manipulate these
cells to provide reliable, safe and effective outcomes in
cell-replacement approaches.
NSCs are immature cells present in the developing and
adult Central Nervous System (CNS). Typically, NSCs are
defined by three cardinal characteristics: self-renewal po-
tential, neural tripotency (i.e., the capability to give rise to
all of the major neural lineages: neurons, astrocytes and
oligodendrocytes) and competence for in vivo regener-
ation (Figure 1; [2]). They have the potential to generate
both neurons and glia of the developing brain and they
also account for the limited regenerative potential in the
adult brain. In the adult CNS, NSCs reside in defined
regions (“neurogenic niches”) that sustain their multi-
potency and regulate the balance between symmetrical
self-renewal and fate-committed asymmetric divisions [3].
Several studies have shown that NSCs can be extracted
from neural tissue or generated from pluripotent cellular
sources, genetically manipulated and differentiated in vitro
[2]. In the past two decades, a variety of protocols for NSCsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Cardinal neural stem cell properties.
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ent conditions have been described. However, beside these
important progresses, the identification of the best sources
for NSCs derivation and the optimization of approaches to
stably proliferate them clonally in vitro still represents a
major goal of NSC research.
Yet, for a realistic exploitation of NSCs for cell therapies,
clinically-suitable NSC systems should hold specific key
properties including (i) standardized production and scal-
ability to good medical practice (GMP), (ii) karyotypic
stability, (iii) ability to correctly integrate in the host tissue
and (iv) differentiate into the required functional neural
cells. In addition, NSCs should exhibit a reproducible, pre-
dictable and safe behavior following in vivo injection.
NSCs in brain organogenesis and homeostasis
In the developing and adult CNS, different NSC popu-
lations dynamically appear following predetermined
spatio-temporal developmental programs. Molecular and
biological characteristics of NSCs greatly vary depending
on the region and developmental stage considered [4].
Development of the vertebrate CNS starts with neural
plate folding to originate the neural tube, consisting of
radially elongated neuroepithelial cells (NEPs) [5]. NEPs
develop definite identities and different fates depending
on their positions along the rostrocaudal (R-C) and dorso-
ventral (D-V) axes of the neural tube. Patterning along the
R-C axis leads to the initial distinction into prosencephalon,
mesencephalon, rhombencephalon and spinal cord territor-
ies. NEPs are accountable for the first wave of neurogenesis
in the neural tube. As development proceeds, NEPs convert
themselves into another transitory NSC type, the so-called
“radial glia” (RG) [6,7]. This rapidly constitutes the main
progenitor cell population in mid/late development and
early postnatal life while disappearing at late postnatal andadult stages. Besides their ability to divide asymmetric-
ally and to serve as progenitors of neurons and glia, RG
cells constitute a scaffold on which neurons migrate in
the developing brain. RG differentiation potential is less
extensive compared to that of NEPs. Along with RG, an-
other population of immature neural cells is constituted by
Basal Progenitors (BPs) [8]. They are generated at early
phases of development by NEPs and at later stages by RG.
BPs mostly undergo one or two rounds of division, gener-
ating one or two pairs of neurons. Hence, BPs may be
considered neurogenic transit-amplifying progenitors that
specifically increase the production of neurons during re-
stricted developmental time periods in definite brain areas
(i.e. cerebral cortex).
At the end of neurogenesis (roughly at birth in mice),
neurogenic RG cells are exhausted and residual RG cells
are converted into a unique astrocyte-like subpopulation
[9]. This population will make up the NSC pool of the
adult brain, endorsed with neurogenesis and gliogenesis
maintainance throughout adult life.
The concept that the adult brain retains the ability to
self-renew some of its neurons has been broadly recog-
nized in the last two decades and has represented a break-
through in neurosciences. Pioneering studies from Altman
and Das already reported the generation of new neurons
in a variety of structures in the adult rat and cat includ-
ing the olfactory bulb, hippocampus, and cerebral cor-
tex [10]. However, their results were widely neglected until
the early 1990s, when the formation of new neurons in
adult rodent brain was clearly demonstrated [11,12]. This
led to the identification of the germinal zones of the adult
brain. These are specialized niches located in the subven-
tricular zone (SVZ) of the lateral ventricle wall and in the
subgranular zone (SGZ) of the dentate gyrus of the hippo-
campus [3]. Whether NSCs reside in other regions of the
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duced in the rodent SVZ migrate to the olfactory bulb fol-
lowing the rostral migratory stream (RMS), an anatomic
structure well characterized in the rodent brain. The NSCs
located in the SVZ, also called type B cells, generate actively
dividing intermediate cells, named type C cells, which
further divide giving rise to neuroblasts, referred to as type
A cells that migrate away from the SVZ. These migrating
neuroblasts are organized in chains that connect the SVZ
to the olfactory bulb (constituting the RMS) where they
gradually mature into functional GABAergic granule
neurons. Fate-mapping studies actually reveal that type B
cells are not developmentally restricted to neuronal lineages
but can give rise also to glial progenies, suggesting they are
authentic tripotent NSCs. The second germinal zone of the
adult mammalian brain is the dentate gyrus of the hippo-
campus. Astrocyte-like NSCs, called type I progenitors,
have been identified within the SGZ facing the dentate
gyrus hilus. They share several properties with the type
B cells of the adult SVZ, although they apparently exhibit a
narrower developmental potential. Type I progenitors likely
divide asymmetrically to produce immature proliferating
progenitors, type II cells. These gradually differentiate into
migrating neuroblasts that travel into the granule cell
layer of the dentate gyrus, where they progressively mature
into functional granule neurons. Differently from the type
B cells of the SVZ, the progeny of type I progenitors does
not migrate long distances, but remains localized in clus-
ters closely connected to the parent cell. Additionally, hip-
pocampal NSCs appear to be developmentally restricted
to become granule neurons; currently, there is no evidence
that type I progenitors can generate mature glial deriva-
tives in vivo.
The discovery of NSCs and neurogenesis in the adult
mammalian CNS has tremendously changed our view of
the plasticity and function of the brain. This has prompted
excitement for the possible exploitement of intrinsic
neurogenic activity to cure brain diseases and rescue brain
function after injury. Mobilization of endogenous NSCs
has thus emerged as a potential therapeutic approach for
neural repair. It is known that brain injury promotes the
proliferation of adjacent NSCs, generating new astrocytes
and neurons [13]. For example, focal ischemia transiently
induces forebrain SVZ cell proliferation and neurogenesis.
The NSCs in the SVZ and DG are also stimulated after
traumatic brain injury or seizures [14], suggesting that
adult neurogenesis may play a role in self-recovery
mechanisms of the brain. However, the amount of
spontaneously produced neuroblasts after brain injury
is highly limited, and their survival and differentiation
into mature neurons are far from obtaining regenera-
tive effects.
It should be emphasized that, although our understand-
ing of NSCs has increased dramatically over the past fewyears, there are still many major gaps regarding their
in vivo control.
NSCs for cell replacement approaches: requirements &
available in vitro systems
A large number of studies have explored grafting behavior
of several NSCs typologies (and their progeny) in a variety
of preclinical studies and in some clinical investigations.
Nevertheless, NSCs used for clinical applications should
be safe, effective and accessible in large amount in GMP
conditions. A variety of different sources for NSCs have
been tested, including fetal- and adult CNS-derived NSCs,
neural progenitors derived from pluripotent cells, and
a range of non-neural stem cells, such as mesenchymal
(MSCs) and bone marrow-derived (BMDSCs) stem cells.
With these issues in mind, it should be remarked that up
to now an ideal NSC system is not yet available to the
clinic. Here, we will restrict our discussion to NSCs de-
rived from neural tissue and from pluripotent stem cells.
Advantages and disadvantages of each source and recent
experimental evidence that highlight their potential use
for clinical applications will be presented.
Fetal- and adult-derived NSCs
The isolation of NSCs from their natural niches and their
expansion in culture have been challenging issues, because
the requirements to maintain these cells in their physio-
logical state are yet poorly understood. In the early ‘90s,
the identification of EGF and FGF-2 as key mitogens
for NSCs led to set up culture conditions that support
extended cell division of cells with NSCs properties [11,12].
Since then, several studies reported that NSCs can be
isolated from various regions of rodent (mouse and rat)
and human brain at several developmental stages as well as
from germinative areas of the adult brain. A widely used
method is to culture NSCs as neurospheres (Figure 2; [15]).
These are free-floating aggregates of neural progenitors,
each, in theory, deriving from a single NSC. Their gen-
eration relies on neural tissue micro-dissection followed
by exposure to defined mitogen-supplemented media.
In such a procedure, primary cells are plated in low-
attachment culture flasks in serum-free media supple-
mented with EGF and/or FGF-2. In these conditions,
differentiating or differentiated cells are supposed to die,
whereas NSCs respond to mitogens, divide and form float-
ing aggregates (primary neurospheres) that can be dissoci-
ated and re-plated to generate secondary neurospheres.
This procedure can be sequentially repeated several times
to expand a NSC population.
Complementary to neurosphere culture is adherent cul-
ture, in which cells are more easily monitored and have
better access to growth factors (Figure 2). In the last dec-
ade, several groups reported the generation and expansion
of adherent NSC lines from neural tissue of rodent and
Figure 2 Sources and in vitro growth protocols for neural stem cell generation and expansion.
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competently expanded as adherent clonal homogeneous
NSC lines by exposure to specific mitogens, such as EGF
and/or FGF2 [16,17]. In these conditions, cells divide sym-
metrically, retaining their tripotential differentiation cap-
acity. Adherent culture regimens have been shown to allow
for cultures with less differentiated cells compared to
the neurosphere assay, where cell–cell contacts and non-
uniform mitogens exposure is thought to stimulate differ-
entiation programs [2].
Although several studies have attempted to provide
comparisons between fetal- and adult-derived NSCs, sys-
tematic side-by-side analyses are still few and do not allow
to draw any solid conclusions. In fact, results might behampered by culture conditions, especially for human
NSCs. Nonetheless, major differences between fetal- and
adult-derived human NSCs have been reported in terms
of both biological and molecular properties. Fetal-derived
human NSCs generally exhibit a shorter doubling time, a
more extensive expansion potential in vitro and better
integrative potential following grafting in animal models
[18-21]. Noteworthy, substantial differences have been also
described when comparing human NSCs derived from dif-
ferent brain areas of the same fetus [22].
NSCs from pluripotent stem cells
Neuralization protocols applied to mouse and human
pluripotent stem cells, including embryonic stem cells
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for the generation of NSCs populations. ESCs are derived
from the inner cell mass (ICM) of blastocyst stage mamma-
lian embryos [23,24]. They are characterized by an intrinsic
capacity for self-renewal and the ability to generate all
cell types derived from the three embryonic germ layers
(pluripotency). In the last years, the advent of iPSC technol-
ogy has completely revolutioned the “pluripotency” field,
avoiding the requirement of embryos as source of rodent
and, most importantly, of human pluripotent stem cells.
Moreover, the use of iPSC opens new possibilities for
studies of human development and disorders, further
increasing the potential biomedical applications of this
type of cells [25]. iPSCs are the product of a reprogram-
ming procedure that allows the conversion of somatic
cells directly into pluripotent cells [26,27]. This tech-
nology is straightforward, robust and since its discovery
has been implemented in terms of efficiency and repro-
ducibility. iPSCs closely resemble ESCs with respect to
expression of pluripotency markers, self-renewal poten-
tial, and multilineage differentiation potential. Both murine
and human pluripotent stem cells can be exposed to neur-
alizing in vitro protocols to generate a large amount of
NSCs or progenitor cells. In these conditions, pluripotent
stem cells undergo progressive lineage restrictions similar
to those observed during normal fetal development, lead-
ing to the generation of a range of distinct neural precur-
sor populations [2].
Generally, two main procedures to generate NSCs from
pluripotent stem cells have been developed. The first
strategy relies on the formation of embryoid bodies (EBs),
three-dimensional (3D) aggregates. EBs recapitulate many
aspects of cell differentiation occurring during early mam-
malian embryogenesis and give rise to cells of the three
germ layers, including neural cells. EBs dissociated and
plated in adhesion on coated plastic surfaces in defined
media will produce rosette-like neural cells corresponding
to the NEPs of the developing brain [28,29]. This NSC
population can be subsequently enriched, although no effi-
cient methods for their extensive expansion have been
reported. EB-independent procedures based on adherent
monolayer protocols have been also described [30,31].
Electrophysiology studies have shown that pluripotent-
derived NSCs efficiently generate fully mature neurons
in vitro, as well as functionally integrated neurons after
transplantation in the mammalian CNS [32,33]. Never-
theless, major limitations to therapeutic applications of
pluripotent-derived NSCs are represented by safety con-
cerns and caveats about their clinical-grade production.
Indeed, grafted pluripotent cells can form teratomas, im-
plying that in a clinical setting residual undifferenti-
ated pluripotent stem cells should be excluded from
the cell preparation before grafting. Protocols for avoiding
teratocarcinoma formation in vivo after transplantation ofESC/iPSCs-derived cells are under scrutiny. In this view,
recent studies have reported the direct conversion of
adult somatic cells into NSCs, thus opening a new path to
generate NSCs without contamination of undifferentiated
pluripotent stem cells [34].
The ability to generate patient-specific iPSCs and NSCs
clearly provides enormous prospective for future personal-
ized medicine, although too little is yet known about these
cells to make any firm prediction.
Possible therapeutic actions of grafted NSCs in different
neurodegenerative conditions
Although the capacity of NSCs to divide and appropriately
differentiate in vitro has attracted much attention for clin-
ical translation, it does not assure that these cells func-
tionally incorporate into the recipient tissue and produce
efficient restoration of compromised functions after graft-
ing. In order to generate therapeutic benefits in specific
neurological diseases, grafted cells have to accomplish a
certain grade of morphological, anatomical and functional
integration into the impaired host CNS tissue.
Neurodegenerative disorders embody a heterogeneous
collection of chronic and progressive diseases charac-
terized by distinct aetiologies, anatomical impairments
and symptoms [35]. Some of these disorders, such as
Huntington’s disease (HD), are acquired in an entirely gen-
etic manner. Alzheimer’s disease (AD), amyotrophic lateral
sclerosis (ALS), and Parkinson’s disease (PD) mainly occur
sporadically, although familiar forms caused by inheritance
of gene mutations are known. On the other hand, the CNS
can also be affected by other non-degenerative conditions,
such as spinal cord injury and stroke, with no genetic herit-
able components.
By virtue of this extreme heterogeneity, different spe-
cific requirements should be envisaged when considering
cell replacement as a possible therapeutic strategy. We can
distinguish between (i) “neuronal” CNS degenerative disor-
ders caused by a prominent loss of specific neuronal popula-
tions and (ii) “non neuronal” CNS degenerative conditions
characterized by loss of non neuronal elements.
In the case of neuronal degeneration, the success of cell
replacement strictly depends on the complexity and accur-
acy of the pattern of connectivity that needs to be restored.
In PD, affected dopaminergic neurons in the substantia
nigra (SN) exert a modulatory action on striatal target cir-
cuits mostly through the release of dopamine. This system
is defined as “paracrine” and even a partial pattern repair
may lead to a significant functional recovery in such condi-
tions. Indeed, in PD the donor cells can be transplanted
directly into the target region to circumvent the problem
of long-distance neuritic growth in the adult CNS. Despite
the ectopic location, if grafted cells are able to re-establish
a regulated and efficient release of dopamine, they can lead
to a clinically relevant functional recovery. However, cell-
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diseases such as HD, ALS, trauma, stroke, and AD, which
are characterized by the need of a complex pattern repair.
Differently, “non neuronal” CNS degenerative syndromes
such as multiple sclerosis (MS) characterized by severe in-
flammation, oligodendroglial degeneration and axonal de-
myelination, represent a good target for cell replacement,
due to their limited requirements for pattern repair [36]. In
MS, grafted cells should produce oligodendrocytes able to
restore axonal myelination in order to lead to a functional
rescue.
It should also be emphasized that although pattern re-
pair is critical to obtain permanent efficacy in the brain,
cells transplanted into the brain may also be beneficial
via the release of molecules that may either stimulate the
regenerative potential of local cells (where present) or
increase the survival of the remaining host elements,
thus slowing disease progression (Figure 3; [37]). Also,
immunomodulatory activity of the grafted cells could
be of benefit in diseases such as MS where a prominent
disease-associated inflammation contributes to the estab-
lishment and progression of the disease (Figure 3).
Current clinical trials involving NSCs for
neurodegenerative diseases
A large number of studies have explored the grafting be-
havior of several NSCs typologies (and their progenies)Figure 3 Therapeutical strategies for neural stem cells exploitation inin preclinical studies. Moreover, a few attempts are already
being made to translate these discoveries into the clinical
setting. Currently, the registry and results database of
publicly and privately supported clinical studies with
human participants conducted around the world (http://
www.clinicaltrial.gov/) reports 880 international clinical tri-
als employing the use of stem cells for treatment of patients
affected by several CNS disorders (query terms: “stem cells
AND nervous system”) among which 89 are testing NSC
injection approaches (query terms: “neural stem cell AND
injection AND nervous system disease”). If restricting
the search to non-tumor diseases, the database returns
51 studies (query terms: “neural stem cell AND injection
AND nervous system disease NOT tumor”) with only 27
of these currently open. Interestingly, if we analyze these
results more carefully, only 5 studies are actually open to
explore the potential clinical relevance of NSCs while the
remaining are testing the regenerative potential of mesen-
chymal stem cells whose actual uselfness in brain diseases
is far from being a solid preclinical reality.
To date, few Phase I and II clinical studies employing
NSCs (a dozen in highly debilitating CNS disorders; de-
tails reported in Table 1) have been performed, with the
main objective to demonstrate safety and practicability and
to explore the potential effectiveness of the treatments.
These clinical trials are testing only few NSCs products,
mainly consisting of fetal-tissue-derived allogenic NSCs.CNS diseases.
Table 1 Clinical trials involving NSCs for neurodegenerative diseases
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product candidate, is a purified population of allogenic
NSCs derived from human fetal (16–20 weeks) brain tis-
sue, sorted using the CD133 marker and expanded in cul-
ture as neurospheres. These cells are routinely stored in a
frozen state and reanimated before transplantation [38,39].
In May 2006 a clinical trial (the first using human NSCs)
was approved at Oregon Health and Science University
(OHSU, Portland, OR, USA) for the use of these cells for
lysosomal storage diseases (ClinicalTrials.gov identifier,
NCT00337636), rare (one in 100,000 children) fatal auto-
somal recessive progressive neurological disorders caused
by mutations in enzymes that ultimately lead to accumula-
tion of neurotoxic lipofuscins. Patients generally lose their
vision, develop seizures and dementia, and die before their
teens. In this application NSCs serve as “Trojan Horses”
to deliver enzymes to other cells within the brain, a con-
cept established in rodent models of enzyme deficiencies.
Preclinical studies indicated that intracerebral grafts into
animal model of infantile neuronal ceroid lipofuscinosis
(NCL, Batten’s disease) integrate into the host brain,
produce and release the defective enzyme resulting in
protection of affected neurons. In this open-label, dose-
escalating phase I trial, single donor HuCNS-SC were
injected into 6 patients with either infantile or late infant-
ile NCL. Enrollment in the trial was limited to patients in
the advanced stages of the disease (patients with signifi-
cant neurological and cognitive impairment, whose devel-
opmental age was demonstrated to be less than two-thirds
of their chronological age). Two dose levels were adminis-
tered with the first 3 patients receiving a target dose of
approximately 500 million cells and the other 3 patients
receiving a target dose of approximately 1 billion cells.
The cells were grafted directly into each patient’s brain
(injections were performed into eight areas of each
child’s brain) and patients received immunosuppression
for 12 months after transplantation. The grafting pro-
cedure and combination with prolonged immune sup-
pression were both well tolerated thus showing a favorable
safety profile with transplanted cells, neurosurgical proced-
ure, and immunosuppression regimen. In addition, trans-
planted cells showed long-term survival. Five patients (one
died for disease) completed the 12-month Phase I study
and were subsequently enrolled in a subsequent four-year,
long-term observational study, with three of the five sur-
viving to the end of the four-year study [40]. Three of the
six patients transplanted with HuCNS-SC cells have now
survived more than five years post-transplant, and it is
noteworthy that each have stable quality-of-life measures,
considering that they suffer a progressive neurodegenera-
tive disorder. Assessment of the patients’ cognitive and
neurological function revealed stable scores in some tests,
but the clinical outcomes were generally consistent with
the expected course of impairment associated with thisneurodegenerative disease with no safety concerns attrib-
uted to the grafts. Examination of the brains from three
patients who expired due to causes related to the under-
lying disease showed evidence of engraftment, migration
and long-term survival of the HuCNS-SC cells following
transplantation and the planned cessation of immunosup-
pression. Grafted cells provided widespread global replace-
ment enzyme and bystander neuroprotection. Although
these results look very promising, more detailed analyses
and a longer patients’ follow up will be fundamental to draw
more solid conclusions. In 2009, the Company completed
the Phase I safety study and in October 2010 embarked on a
Phase Ib safety and efficacy trial (clinicaltrials.gov identifier
no. NCT01238315) in 6 children with less advanced Batten’s
disease and therefore most likely to benefit from a timely
neural stem cell transplant. However, the study was discon-
tinued because of the failure to enroll patients meeting the
study criteria (out of 22 initial prospects, none of them met
the entry criteria).
A second open-label phase I clinical trial (ClinicalTrials.
gov NCT01005004) has been sponsored by StemCell
Inc. at the University of California, San Francisco (UCSF)
using HuCNS-SC brain transplantation for Pelizaeus-
Merzbacher disease (PMD). PMD is a X-linked congenital
leukodystrophy characterized by defective myelination [41].
Preclinical studies in animal models showed that intracere-
bral injection of HuCNS-SC produced oligodendrocytes
leading to remylination of neurons affected by the mutated
gene for PMD [42]. This phase I clinical trial has enrolled
four young children with an early severe form of PMD.
Each patient received a total brain dose of 300 million cells
through two injections into the frontal white matter area
of each hemisphere. Immunosuppression was administered
for 9 months following transplantation. The patients have
been followed for twelve months after transplantation; dur-
ing this period they underwent regular neurological as-
sessments and MRI analyses. Data regarding this clinical
trial have been published in October 2012, indicating a
good safety profile for the HuCNS-SC cells and the trans-
plantation procedure [43]. Clinical assessment revealed
small gains in motor and cognitive function in three of
the four patients; the fourth patient remained clinically
stable. Moreover, MRI inspections suggest myelination
in the region of the transplantation, which progressed
over time and persisted after the withdrawal of immuno-
suppression at nine months. Upon completion of the Phase
I trial, all four patients have been enrolled into a 4-year
long-term follow up study.
StemCells Inc. has also sponsored a Phase I/II clinical
trial (clinicaltrials.gov identifier no. NCT01321333) at the
University Hospital Balgrist (Zurich, Switzerland) for assay-
ing safety and preliminary efficacy of intramedullary spinal
cord transplantation of human HuCNS-SC neurospheres
in subjects with thoracic (T2-T11) spinal cord trauma. The
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suffered spinal cord injury (SCI) in the 3 to 12 months
prior to cell transplantation. Each subject received a total
fixed dose of approximately 20 million cells injected dir-
ectly into the thoracic spinal cord near the injury. The first
patients have been transplanted with no safety concerns
arising concerning the surgery and the cellular transplant
[44]. This trial is estimated to end in March 2016. In No-
vember 2012 the consequential long-term follow up of the
12 patients subjected to HuCNS-SC transplantation has
started and it will last until March 2018 (clinicaltrials.gov
identifier no. NCT01725880).
Recently, also Neuralstem Inc. has received FDA ap-
proval to initiate a Phase I safety trial using proprietary
NSCs for chronic spinal cord injury (clinicaltrials.gov
identifier no. NCT01772810). The cell line used in this
trial (NSI-566RSC) is derived from the cervical and upper
thoracic regions of the spinal cord from a single 8-week
human fetus after an elective abortion [45]. The cells are
serially expanded as monolayer in serum-free media sup-
plemented with FGF-2 as the sole mitogen to maintain
proliferation and prevent differentiation. This trial will
enroll up to eight SCI patients with thoracic lesions (T2-
T12) one to two years post-injury with no motor or sen-
sory function in the relevant segments at and below injury
(complete paralysis). All patients in the trial will receive
six injections close to injury site with the first four patients
receiving 100,000 cells per injection and the second four
patients 200,000 cells per injection. The patients will
also receive immunosuppressive therapy, which will last
for three months, as tolerated. Late this year, Neuralstem
Inc. will also start an acute spinal cord injury trial in Seoul
in collaboration with their South Korean partner CJ
CheilJedang.
NSI-566 NSCs have also been used in clinical trials
for the treatment of ALS (Lou Gehrig’s disease). In 2009
Neuralstem Inc. sponsored the first NSC-based phase
I safety trial in ALS (clinicaltrials.gov identifier no.
NCT01348451) at the Emory University School of Medicine
(Atlanta, GA, USA). The trial enrolled 18 patients divided
in 5 groups characterized by slightly different inclusion cri-
teria and receiving different procedures in terms of site and
number of injections (number of cells/injection: 100,000).
The first group (cohort A) included patients with advanced
ALS who are unable to walk, and received transplant injec-
tions in one or both sides of the lower spinal cord. The trial
then progressed to patients who were still ambulatory. The
first three of these patients (Cohort B) received five unilat-
eral injections while the next three patients (Cohort C) re-
ceived ten bilateral injections in the same lumbar region.
In 2011 Neuralstem received approval to move into the
cervical (upper back) stage of the trial. In this stage,
two groups of three patients each were included. The
first three of these patients (Cohort D) were ambulatorywith some arm dysfunction and received grafts on one
side of their neck. The last group (Cohort E) included
ALS patients still ambulatory, who received both injec-
tions on one side of their neck and injections on both
sides of their lower spine. The last patient in this Phase
I trial was treated in August 2012 and the trial was con-
cluded in February 2013. The clinical assessments on
the first 12 grafted patients demonstrated no evidence
of acceleration of disease progression with the planned
18 months post-transplantation follow up [46]. In April
2013, following conclusion of its Phase I FDA-approved
trial, Neuralstem received approval to start a Phase II dose
escalation and safety trial (clinicaltrials.gov identifier no.
NCT01730716) to be performed in three centers: Emory
University Hospital in Atlanta, Georgia, site of Phase I;
ALS Clinic at the University of Michigan Health System,
in Ann Arbor, Michigan, and Massachusetts General Hos-
pital in Boston. This Phase II trial is designed to treat up
to 15 ambulatory patients, in five different dosing cohorts,
advancing up to a maximum of 40 injections, and 400,000
cells per injection based on safety. The first 12 patients
will receive injections in the cervical region of the spinal
cord only, where the stem cells could help preserve
breathing function. The final three patients will receive
both cervical and lumbar injections.
Another ALS Phase I clinical trial using allogenic fetal
brain-derived human NSCs has been approved to the
Azienda Ospedaliera Santa Maria (Terni, Italy) in June
2012. This study includes a total of 18 ALS patients
that will be treated with intraspinal implanted allogeneic
foetal-derived neurospheres (clinicaltrials.gov identifier no.
NCT01640067).
Fetal NSCs are also being used for treatment of disabled
ischemic stroke patients by the company ReNeuron Lim-
ited (UK). For this clinical application, ReNeuron uses
its proprietary allogenic foetal-derived brain human NSCs
(CTX0E03), which were derived from human fetal brain
tissue following genetic modification with a conditional
immortalizing gene, c-mycER [47]. This transgene gener-
ates a fusion protein that stimulates cell proliferation in
the presence of a synthetic drug, 4-hydroxy-tamoxifen
(4-OHT). The cell line is clonal, expands rapidly in culture
and has a normal human karyotype (46 XY). In the absence
of growth factors and 4-OHT, the cells undergo growth
arrest and differentiate into neurons and astrocytes.
The Phase I clinical trial (clinicaltrials.gov identifier no.
NCT01151124) started on June 2012 at the Glasgow
Southern General Hospital (Glasgow, Scotland). The study
is designed to test the safety of CTX0E03 NSCs product
by direct single dose injection into the damaged brains of
12 male patients 60 years of age or over who remain mod-
erately to severely disabled 6 months to 5 years following
an ischemic stroke. The trial will consider four ascending
doses of CTX0E03 cells (4 dosage groups of three patients
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or 20 million cells). Clinical outcomes will be measured
over 24 months and patients will be invited to participate
in a long-term follow-up trial for a further 8 years.
To date, only one study has exploited the use of human
ES-derived neural cells for the treatment of CNS injury in
a clinical setting. In 2010, Geron Corporation started a
Phase I Safety clinical trial with human ES cell-derived
oligodendrocyte progenitors (GRNOPC1 cells) [48-50]
in patients with neurologically complete, subacute spinal
cord injury (ClinicalTrials.gov identifier: NCT01217008).
The study was designed to test the safety of the Geron
GRNOPC1 cell product by direct single dose (2 million
cells) injection into the damaged spinal cord of five patients
with neurologically complete spinal cord injuries (between
7 and 14 days post injury). The enthusiasm about this study
was abated only a year later, when Geron suddenly and sur-
prisingly stopped the trial and decided to give up on the
stem cell division. In 2013 Asterias Biotherapeutics, Inc., a
subsidiary of BioTime, purchased Geron’s stem cell division
and announced that it will resume the spinal cord trial.
Is there a rationale for stem cell-based treatments for
neurodevelopmental disorders?
An increasing number of recent studies indicate that
neurological and neuropsychiatric disorders including epi-
lepsy, autism and schizophrenia may arise from altered
brain development. According to this view, neurodevelop-
mental disorders may emerge from altered neurogenetic
processes that lead to misplacement or loss of neurons
and their connections in the postnatal brain. It is therefore
not surprising that, in recent years, much attention has
been paid to the possible use of NSCs to understand (and
possibly treat) these pathologies. Currently, NSCs trans-
plantation strategies have been essentially tested in rodent
models of temporal lobe epilepsy (TLE). In both humans
and rodents, TLE is accompanied by massive cell loss in
the hippocampus and limbic areas [51]. In the past ten
years, NSCs transplantation (both during the latent and
chronic phases) has been widely tested as a tool to coun-
teract cell loss and ameliorate TLE symptoms in rodents.
NSCs are attractive as donor cells for grafting in TLE for a
number of reasons: 1) they can be expanded in culture for
extended periods; 2) they migrate extensively into the
hippocampal layers; 3) they can differentiate into inhibi-
tory GABAergic neurons as well as astrocytes secreting
anticonvulsant factors (such as the glial cell-line derived
neurotrophic factor GDNF); 4) they produce neurotrophic
factors that can stimulate hippocampal neurogenesis from
endogenous pools of NSCs [52]. Different strategies have
been used to test the protective effects of transplanted
NSCs, including transplantation of embryonic or adult
hippocampal NSCs in both the KA and pilocarpine
models of TLE [52]. Antiepileptic and neuroprotectiveeffects have also been reported after transplantation of
different types of stem cells. Grafting of human umbilical
cord stem cells [53] or genetically-engineered bone marrow
mesenchymal stem cells [54] have been shown to amelior-
ate seizures in the pilocarpine rat model of TLE.
Currently, research performed on animal models does
not provide a rationale for the use of stem cells in neu-
rodevelopmental disorders, with the only exception of
epilepsy. Indeed, massive cell loss is detected in the epi-
leptic brain, thus offering a rationale for cell replacement
therapies. On the contrary, current research does not
support the idea that stem cell transplantation may work
in the case of other neurodevelopmental disorders such as
autism, since no massive cell loss is observed in the brain
of autistic patients. Accordingly, a Phase I trial to test the
effect of stem cells transplantation in 20 patients with
temporal lobe epilepsy is currently ongoing (clinicaltrials.
gov identifier no. NCT00916266). The study, authorized
on July 2008 to the Instituto do Cerebro de Brasilia (Brazil),
has the aim to evaluate autologous bone marrow derived
stem cells (BMDSCs) transplantation as a safe and poten-
tially beneficial treatment for patients with temporal lobe
refractory epilepsy. As primary outcomes were considered
evaluation of seizure frequency, hippocampal volume and
cognitive performance. Although the study should have
been completed in June 2012, no results are currently
available. Beyond the lack of solid results, it should be
emphasized that the rationale for using BMDSCs trans-
plantation in TLE patients is rather inappropriate, since
these cells can not replace neural cell lost in these pa-
tients (see also below, “Clinical testing of non-neural cells
for CNS diseases”).
More surprisingly, one completed and five ongoing tri-
als have been approved to test the efficacy of stem cell
transplantation in patients affected by autism spectrum
disorders (query terms: “stem cells AND autism”) (details
are reported in Table 2). None of these studies is actually
injecting NSCs or pluripotent cells derivatives: they
are focussed on using autologous BMSC (clinicaltrials.
gov identifier no. NCT01740869, NCT01974973), adipose-
derived MSC (clinicaltrials.gov identifier no. NCT01502488)
and human cord blood mononuclear cells (clinicaltrials.gov
identifier no. NCT01343511, NCT01638819, NCT01836562).
Considering the young age and the overall number of
patients enrolled (more than 350), the poor rationale
and the total absence of published reports from these
studies, great attention should be payed to these trials.
Retinal dystrophies and stem cell treatments
Another field in which a strong interest has been raised for
cell treatments based on NSCs or cell derivatives of human
pluripotent stem cells is represented by retinopathies. Many
studies are undergoing in order to characterize the appro-
priate source of cells for these therapeutic approaches. The
Table 2 Clinical trials for neurodevelopmental disorderss
NCT number Title Recruitment Conditions Interventions Sponsor/
Collaborators
Phases Enrollment Start date Completion
date
NCT01343511 Safety and Efficacy of
Stem Cell Therapy in
Patients With Autism
Completed Autism Biological: human cord blood
mononuclear cells implantation|
Biological: human cord blood









Phase 1-2 37 March 2009 May 2011
NCT01502488 Adipose Derived Stem
Cell Therapy for Autism
Not yet
recruiting






Phase 1-2 10 October 2014 January
2017
NCT01638819 Autologous Cord Blood
Stem Cells for Autism
Recruiting Autism Biological: Autologous Cord
Blood Stem Cells Injection|
Biological: Placebo
Sutter Health Phase 2 30 August 2012 August
2014
NCT01740869 Autologous Bone Marrow




Biological: Stem cells Injection Hospital Universitario
Dr. Jose E. Gonzalez
Phase 1-2 30 November 2012 Not
specified
NCT01836562 A Clinical Trial to Study the
Safety and Efficacy of Bone
Marrow Derived Autologous
Cells for the Treatment of
Autism
Recruiting Autism Biological: Autologous Cord
Blood Stem Cells Injection
Chaitanya Hospital,
Pune
Phase 1-2 100 March 2011 April 2014









in patients with autism
Neurogen Brain and
Spine Institute
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http://www.molcelltherapies.com/content/2/1/31retina is subject to different degenerative diseases, which
can be both age related (such as AMD, Age-related
Macular Degeneration) and inherited (LCA, Leber’s Con-
genital Amaurosis, and RP, Retinitis pigmentosa). These are
all characterized by degeneration of photoreceptors and/or
retinal pigmented epithelium (RPE cells). A number of dif-
ferent therapeutical approaches have been meaningfully
explored to cure human photoreceptor degenerations.
These include environmental modifications (nutrient sup-
plementation and avoidance of light), drugs (i.e. neuro-
trophic factors), gene therapy to provide the healthy
version of the mutated gene, retinal prostheses [55].
A large body of transplantation studies has been carried
out in order to assess the molecular features characterizing
cells with the ability to integrate and generate functional
photoreceptors in degenerating retinae. These studies de-
fined that, in rodents, integration of donor cells is best
obtained by using post-mitotic photoreceptor precursors
[56,57]. They also showed that, for donor cells to integrate
in retinal tissue, they should have specific molecular char-
acteristics and should be derived from retinae that have
not reached complete maturation. Despite the promise,
the low numbers of integrating cells impaired a real func-
tional recovery in the transplanted eyes, even if some res-
toration of vision was observed [58]. Moreover, a possible
transition to the clinic would be blocked by the obvious
ethical concerns in the use of human retinal progenitor
cells. For these reasons, many reseachers turned their at-
tention to obtaining postmitotic photoreceptor precursors
in vitro, by differentiation of pluripotent cells such as ESCs
and iPSCs. Integration capabilities of the in vitro differen-
tiated cells have also been tested by subretinal injections
in mice [59-61]. All these studies assessed terminal differ-
entiation and integration of pluripotent cells-derived
photoreceptors and, when possible, functionality, although
showing alternative results.
To date, the clinicaltrials.gov registry reports 50 inter-
national clinical trials employing different stem cells types
(query terms: “stem cells AND retinopathy”), mostly au-
tologous BMSCs, for treatment of patients affected by
retinal dystrophies. Among these, an age related macular
degneration (AMD) Phase I/II trial sponsored by Stem Cell
Inc. is ongoing in three US centers: (Byers Eye Institute
at Stanford, Stanford Hospital and Clinics, Palo Alto,
California; New York Eye and Ear Infirmary, New York;
Retina Foundation of the Southwest Recruiting Dallas,
Texas) (clinicaltrials.gov identifier no. NCT01632527). This
study, involving 16 patients affected by geographic atrophy
secondary to AMD, is designed to investigate the safety
and preliminary efficacy of unilateral subretinal transplant-
ation of HuCNS-SC cells by means of a single transplant
procedure. Immunosuppressive agents will be administered
orally to all subjects for a period of three months after sur-
gery. Participants will be monitored for complications aswell as structural evidence of successful engraftment and
changes to vision.
Interestingly, the field of retinopathies represents the
arena where the largest number of human ESC-derived
products is being tested in the clinics. Currently, seven
trials are open employing terminally differentiated hu-
man ESC-derived hRPE (details are reported in Table 3).
Six of these studies are sponsored by Advanced Cell Tech-
nology (ACT; USA) and CHA Bio & Diostech (South
Korea) for the use of the ACT’s MA09-hRPE cells for treat-
ment of Stargardt’s Macular Dystrophy patients (SMD;
clinicaltrials.gov identifier no. NCT01469832, NCT01345006
and NCT01625559), dry AMD patients (clinicaltrials.gov
identifier no. NCT01674829, NCT01344993) or Myopic
Macular Degeneration patients (MMD; clinicaltrials.gov
identifier no. NCT02122159). In these studies, the num-
ber of grafted cells varies between 50,000 and 200,000
cells in order to define the optimal dosage. The prelim-
inary results of two of these trials have been published,
showing safety and some promising efficacy in vision
restoration. For this reason, MA09-hRPE cells from ACT
have been recently granted by the FDA the orphan drug
designation for use in the treatment of Stargardt’s Macular
Dystrophy (SMD). This represents the first time that
orphan drug status has been granted for the use of an
embryonic stem cell derived therapy in treating an un-
met medical need. As a result, ACT is entitled to obtain
several benefits aimed at forstering clinical exploitation
of this cell product, including tax credits, access to grant
funding for clinical trials, accelerated FDA approval and
allowance for marketing exclusivity after drug approval for
a period of as long as seven years.
The remaining study is represented by a non-randomized
safety/efficacy study phase I open label trial of RPE replace-
ment aiming at evaluating the safety and feasibility/efficacy
of treating subjects with wet AMD in whom there is
rapidly progressing vision loss (clinicaltrials.gov identifier
no. NCT01691261). The study has been sponsored by
Pfizer and will be performed at University College,
London (UK). It will include 10 patients that will receive
Pf-05206388 RPE cells immobilized on a polyester mem-
brane as a monolayer, derived from human ESCs. The im-
planted membrane is approximately 6 mm × 3 mm and is
intended to be life-long.
Clinical testing of non-neural cells for CNS diseases
While in this review we have mainly discussed ongoing
clinical studies based on human NSCs or neural deriva-
tives of pluripotent stem cells, most of the currently
open Phase I/II clinical trials for treatment of brain dis-
eases are actually testing therapeutic potential of cells of
non-neural origin. Mesenchymal stem cells (MSCs) de-
rived from bone marrow (BMD-MSCs) or adipose tissue
and bone marrow derived stem cells (BMDSCs) have been
Table 3 Clinical trials involving stem cells for retinal dystrophies
NCT number Title Recruitment Conditions Interventions Sponsor/
Collaborators
Phases Enrollment Start date Completion
date
NCT01344993 Safety and Tolerability of
Sub-retinal Transplantation
of hESC Derived RPE
(MA09-hRPE) Cells in Patients
With Advanced Dry Age Related
Macular Degeneration












of hESC Derived RPE (MA09-hRPE)













NCT01469832 Safety and Tolerability of
Sub-retinal Transplantation
of Human Embryonic Stem
Cell Derived Retinal Pigmented
















NCT01625559 Safety and Tolerability of














NCT01632527 Study of Human Central
Nervous System Stem Cells
(HuCNS-SC) in Age-Related
Macular Degeneration (AMD)










NCT01674829 A Phase I/IIa, Open-Label,
Single-Center, Prospective Study
to Determine the Safety and
Tolerability of Sub-retinal
Transplantation of Human
Embryonic Stem Cell Derived
Retinal Pigmented Epithelial
(MA09-hRPE) Cells in Patients
With Advanced Dry Age-related
Macular Degeneration (AMD)











NCT01691261 A Study Of Implantation Of
Human Embryonic Stem Cell
Derived Retinal Pigment
Epithelium In Subjects With
Acute Wet Age Related
Macular Degeneration And
Recent Rapid Vision Decline











NCT02122159 Research With Retinal Cells
Derived From Stem Cells for
Myopic Macular Degeneration
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liable extra-neural sources of multipotential stem cells for
brain repair [62,63]. From a clinical point of view, these
non-neural cell sources provide the advantage of easy
accessibility and of autologous approaches, thus minimizing
immune reactions. Nonetheless, although these cells have
been widely used in clinical settings for non neural diseases
and their safety has been demonstrated when injected in
several body districts (different from the CNS), particularly
with autologous transplants, their sustained therapeutic
benefit for brain disorders has not been consistently ob-
tained, neither in preclinical nor in clinical studies. Several
optimistic reports have been published regarding MSCs
conversion into NSCs or neurons but actually the proof of
functional neurons generation from MSCs is still missing.
Indeed, these reports based their conclusions on morpho-
logical inspection or on the expression of few neuronal
markers rather than demonstrating that these neuronal-
like cells exhibit all the morphological, antigenic and
functional key properties of neurons (i.e. presence of
mature synaptic structures, electrical excitability, controlled
neurotransmitter release) or showing an effect in disease
models [64,65]. Overall, the currently available evidences
indicate that the number of BMDSCs or MSCs able to
differentiate into neurons, if any, is extremely low and
irrelevant when thinking of their potential clinical exploit-
ation. However, several laboratories continue to declare that
MSCs can be converted into neurons, thus encouraging
many unsubstantiated clinical trials testing these cells for
brain repair. To this regard, the clinical outcome published
in 2010 regarding the first open-label pilot clinical trial with
autologous BMD-MSCs transplanted into the striatum of
patients with advanced Parkinson’s Disease is emblematic
[66]. Seven PD patients aged 22 to 62 years received a
single-dose (1 million per kg body weight) unilateral trans-
plantation of autologous cells into the sublateral ventricular
zone by stereotaxic surgery. Patients were followed up for a
period that ranged from 10 to 36 months and the results
indicate that the protocol seems to be safe with no adverse
events occurring during the observation period. Nonethe-
less, the number of patients recruited and the uncontrolled
type of trial did not permit demonstration of effectiveness
of the treatment. Indeed, the clinical improvements were
only marginal and possibly due to a placebo effect. Regard-
less of the capability of MSCs to differentiate into neurons,
many trials have been pushed by the belief that MSCs
might provide benefit to patients affected from brain
diseases by virtue of neuroprotective/immunomodulatory
properties, thus supporting diseased cells and controlling
or adjusting inflammation within the patient’s CNS. As
such, many preclinical studies have been performed with
MSCs but at the present time it is yet unproven that they
might exert substantial and enduring effects in any neuro-
logical condition. Finally, long-term follow up should beperformed in order to be confident about the safety of
injecting MSCs (or any other non-neural cell type) in the
brain. Indeed, it is still unknown (i) what eventually
happens to these cells in the brain, (ii) if they survive long
term in the lesioned region and (iii) if their “ectopic nature”
might induce adverse effects in the future.
Beside the use of MSCs and BD-MSCs, hematopoietic
stem cells (HSCs) represent an interesting source of non
neural cells, exploitable for treating some CNS disorders.
Indeed, HSCs have shown very promising clinical results
for gene therapy treatments of congenital leukodystrophies
[67,68].
Conclusions
NSCs have become one of the most intensively studied
cell types in biology. Our knowledge of their identities
and properties has been radically revolutionized by the
possibility to isolate and expand them in vitro. One can
anticipate that a rigorous assessment of the functional qual-
ities of NSCs combined with emerging knowledge of CNS
microenvironment following injury will allow us to exploit
the advantages offered by these cells in the clinical setting.
It should be emphasized that the NSCs potential to regen-
erate the brain relies also on the competence of other cells
to contribute to repairing processes. NSCs and pluripotent
stem cells neural derivatives are now under scrutiny in early
Phase I/II trials for CNS disorders. Also new systems based
on direct conversion of non neural cells into NSCs and
into specific neuronal populations are bringing new pos-
sible strategies of intervention. While it is yet too early to
predict the outcome of these trials, initial results indicate
no safety concerns. Although the field is moving forward
every year and new trials are continuously being planned
and started, to date none was successful, thus reducing the
hope that stem cells may be a valid CNS therapy in the
next few years.
Before envisaging any therapeutic application of such
cells for CNS disorders, we need to confront several, and
still unsolved, problems: (i) the ideal stem cell source for
transplantation in each specific disease context; (ii) the ap-
propriate number of cells to transplant; (iii) a clinically-
applicable transplantation strategy; (iv) the right disease
stage for cell transplantation; and, finally, (v) the most
appropriate in vivo and/or in vitro manipulations to obtain
the proper cells to be transplanted. With time, progress
will be made, but it is only by following a correct preclin-
ical research and well-established methods of translation
from the laboratory to the clinic that this can happen. The
growing interest and participation in stem cell therapies
of big pharmaceutical companies and their collaborating
partners worldwide will represent an important step in
order to increase the number of new well-defined clinical
trials in the next few years. It is mandatory that scientists
and clinicians should work side by side in order to pay
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to move to clinic and to responsibly communicate to
the public and patients [69]. The real risk is that the en-
tire field of stem cell research and therapies might become
a fertile ground for commercially driven illusion sellers
that peddle the poisoning concept of stem cell research as
an alchemic science.
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